Do analysts rate APVO or KZIA?

Novogen has a consensus price target of $23.75, suggesting a potential upside of 64.37%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has preferable valuation and earnings, APVO or KZIA?

Novogen has higher revenue and earnings than Aptevo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Novogen $30K 794.70 -$13.41M N/A N/A

Is APVO or KZIA more profitable?

Novogen's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Novogen N/A N/A N/A

Do analysts rate APVO or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 700.78%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is APVO or ALLR more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Allarity Therapeutics N/A -109.94% -47.27%

Do analysts prefer TXMD or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better earnings & valuation, CLRB or APVO?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is CLRB or APVO more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts recommend APVO or MRKR?

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 584.93%. Given Marker Therapeutics' higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Aptevo Therapeutics (APVO) Competitors

$4.48 -0.07 (-1.60%)

As of 11:45 AM Eastern

Compare

APVO vs. KZIA, ALLR, TXMD, CLRB, and MRKR

Should you buy Aptevo Therapeutics stock or one of its competitors? MarketBeat compares Aptevo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptevo Therapeutics include Novogen (KZIA), Allarity Therapeutics (ALLR), TherapeuticsMD (TXMD), Cellectar Biosciences (CLRB), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does Aptevo Therapeutics compare to Novogen?

Aptevo Therapeutics (NASDAQ:APVO) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Aptevo Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Novogen has a consensus price target of $23.75, suggesting a potential upside of 64.37%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.89 beat Novogen's score of 1.87 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Novogen	Very Positive

Novogen's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Novogen	N/A	N/A	N/A

Novogen has higher revenue and earnings than Aptevo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Novogen	$30K	794.70	-$13.41M	N/A	N/A

Summary

Novogen beats Aptevo Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Allarity Therapeutics had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Allarity Therapeutics' score of 1.36 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Allarity Therapeutics	Positive

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Aptevo Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Allarity Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Allarity Therapeutics	$320K	63.64	-$11.23M	-$0.72	N/A

Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 700.78%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allarity Therapeutics beats Aptevo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aptevo Therapeutics compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

TherapeuticsMD has a net margin of 5.34% compared to Aptevo Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

TherapeuticsMD has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

TherapeuticsMD has higher revenue and earnings than Aptevo Therapeutics. Aptevo Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.73	-$570K	$0.06	38.00
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Aptevo Therapeutics	Very Positive

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

TherapeuticsMD beats Aptevo Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 311.21%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Aptevo Therapeutics' return on equity of -198.50% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Cellectar Biosciences' score of 1.16 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Aptevo Therapeutics	Very Positive

Summary

Cellectar Biosciences beats Aptevo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Marker Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Aptevo Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Marker Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.61	N/A

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.89 beat Marker Therapeutics' score of 0.96 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Marker Therapeutics	Positive

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aptevo Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 584.93%. Given Marker Therapeutics' higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Marker Therapeutics beats Aptevo Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.64M	$3.64B	$6.76B	$12.51B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.02	21.05	25.78	24.73
Price / Sales	N/A	343.87	548.02	103.35
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	0.26	8.74	10.84	6.52
Net Income	-$25.97M	$23.81M	$3.57B	$336.86M
7 Day Performance	-3.30%	3.68%	2.43%	1.31%
1 Month Performance	-8.82%	1.64%	0.76%	0.36%
1 Year Performance	-91.85%	69.92%	36.68%	30.89%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	1.3606 of 5 stars	$4.48 -1.6%	N/A	-91.8%	$5.64M	N/A	N/A	50	News Coverage Positive News Gap Down
KZIA Novogen	2.4256 of 5 stars	$13.86 flat	$23.75 +71.4%	+128.1%	$22.92M	$30K	N/A	12	Positive News
ALLR Allarity Therapeutics	2.3059 of 5 stars	$1.43 flat	$10.25 +616.8%	+30.0%	$22.75M	$345K	N/A	10	News Coverage Positive News
TXMD TherapeuticsMD	1.6878 of 5 stars	$1.95 flat	N/A	+100.0%	$22.57M	$3.02M	32.50	420	Gap Up
CLRB Cellectar Biosciences	4.5284 of 5 stars	$2.79 flat	$11.00 +294.3%	-67.1%	$22.30M	N/A	N/A	10	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. KZIA, ALLR, TXMD, CLRB, and MRKR

How does Aptevo Therapeutics compare to Novogen?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Summary

How does Aptevo Therapeutics compare to TherapeuticsMD?

Summary

How does Aptevo Therapeutics compare to Cellectar Biosciences?

Summary

How does Aptevo Therapeutics compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. KZIA, ALLR, TXMD, CLRB, and MRKR

How does Aptevo Therapeutics compare to Novogen?

Which has more risk and volatility, APVO or KZIA?

Do institutionals and insiders have more ownership in APVO or KZIA?

Do analysts rate APVO or KZIA?

Does the media prefer APVO or KZIA?

Is APVO or KZIA more profitable?

Which has preferable valuation and earnings, APVO or KZIA?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Do institutionals & insiders hold more shares of APVO or ALLR?

Does the media prefer APVO or ALLR?

Is APVO or ALLR more profitable?

Which has more volatility and risk, APVO or ALLR?

Which has better valuation & earnings, APVO or ALLR?

Do analysts rate APVO or ALLR?

Summary

How does Aptevo Therapeutics compare to TherapeuticsMD?

Is TXMD or APVO more profitable?

Which has more volatility and risk, TXMD or APVO?

Do analysts prefer TXMD or APVO?

Which has higher earnings and valuation, TXMD or APVO?

Does the media refer more to TXMD or APVO?

Do institutionals and insiders believe in TXMD or APVO?

Summary

How does Aptevo Therapeutics compare to Cellectar Biosciences?

Do analysts prefer CLRB or APVO?

Which has more risk & volatility, CLRB or APVO?

Is CLRB or APVO more profitable?

Which has better earnings & valuation, CLRB or APVO?

Do institutionals & insiders have more ownership in CLRB or APVO?

Does the media favor CLRB or APVO?

Summary

How does Aptevo Therapeutics compare to Marker Therapeutics?

Is APVO or MRKR more profitable?

Which has higher valuation & earnings, APVO or MRKR?

Does the media prefer APVO or MRKR?

Do insiders & institutionals believe in APVO or MRKR?

Which has more volatility and risk, APVO or MRKR?

Do analysts recommend APVO or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools